Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Paige›
Analysis
AddedFeb 27, 2023
UpdatedJun 18, 2026
Paige

Paige

Series C

A clinical AI company that utilizes computational pathology for cancer discovery and treatment.

HQ
New York City, NY, US
Founded
2018
Loading
Overview
Analysis
Compare
Fundraising
Employees
Website

Contents

  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy
  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy

Product Overview

Paige is a computational pathology company that offers an artificial intelligence (AI) platform for pathologists and researchers to improve their workflow and ultimately enhance patient care. The company’s platform uses deep learning algorithms to assist pathologists in analyzing medical images, such as those from tissue biopsies, to help them make more accurate and timely diagnoses.

One of Paige’s main features is its ability to analyze large volumes of medical images quickly and accurately, which can help pathologists to identify patterns and anomalies that may be difficult to detect with the human eye alone. It also offers a range of tools and analytics that can help pathologists to make more informed decisions about patient care, such as by providing insights into disease progression and treatment options.

Specifically designed to integrate with existing healthcare systems and workflows, Paige makes it easier for pathologists and researchers to adopt the technology and incorporate it into their daily practice. Additionally, it is built using a privacy-by-design approach, which ensures that patient data is protected and that the platform is compliant with relevant regulatory requirements.

Competitive Advantages

Paige's primary competitive advantage is its cutting-edge AI platform that offers unique solutions to the healthcare industry, specifically to pathologists and researchers. The company's platform was built using advanced deep learning algorithms that enable the system to accurately analyze large volumes of medical images, such as tissue biopsies, which can be difficult for pathologists to interpret accurately. This helps pathologists make more informed decisions about patient care, leading to better outcomes for patients.

Another advantage of Paige's platform is its ability to integrate with existing healthcare systems and workflows, making it easier for healthcare organizations to adopt and implement the technology. The company's privacy-by-design approach is also a significant competitive advantage, as it ensures that patient data is protected and that the platform is compliant with relevant regulatory requirements.

Paige is also differentiated from its competitors by its focus on pathology and its deep understanding of the needs of pathologists and researchers. The company's team includes leading experts in AI, pathology, and oncology, who have worked to develop a platform that meets the specific needs of the pathology community. This expertise and focus on pathology set the company apart from competitors that offer more general AI solutions for the healthcare industry.

Overall, Paige.AI's competitive advantage lies in its cutting-edge technology, focus on pathology, and expertise in AI and healthcare. These factors make Paige.AI a strong contender in the computational pathology market.

Competitive Disadvantages

As a company that develops AI-powered diagnostic tools to assist pathologists and clinicians in the detection and diagnosis of cancer, Paige has a competitive disadvantage that can be attributed to several factors:

Limited Data: One of the major challenges in developing robust AI-based diagnostic tools is the availability of large datasets for training and testing. Paige is a relatively new company with limited access to large-scale datasets compared to more established players in the market, which can limit the performance of their algorithms.

Regulatory Hurdles: The development and deployment of AI-based diagnostic tools require regulatory approval, which can be a time-consuming and costly process. Paige may face challenges in consistently obtaining regulatory approval for its products, which can delay their entry into the market.

Established Competitors: The healthcare technology market is highly competitive, with several established players already offering AI-powered diagnostic tools for cancer detection and diagnosis. Paige will need to compete with these players who already have established customer bases and brand recognition.

Integration with Existing Systems: Another challenge that Paige may face is integrating their diagnostic tools with existing healthcare systems used by hospitals and clinics. This can be a complex process, and any issues with integration can limit the adoption of their products by healthcare providers.

Overall, while Paige AI has developed promising technology, the company may face significant challenges in overcoming these competitive disadvantages to establish itself as a leader in the computational pathology market.

Pricing Strategy

Paige's pricing strategy is not publicly available, as the company typically works with healthcare organizations and institutions on a case-by-case basis to provide tailored solutions. However, it is likely that Paige follows a subscription-based pricing model, where customers pay a recurring fee for access to the platform's features and services.

The exact cost of Paige's platform will depend on a range of factors, including the size of the organization, the scope of the project, and the level of support and customization required. As such, the company's pricing is likely to be highly flexible and adaptable to meet the specific needs of each customer.

In terms of its pricing strategy relative to competitors, Paige is in a unique position in the computational pathology (CPATH) market, as there are few other companies that offer a comparable AI platform for pathologists and researchers. However, other CPATH companies that provide AI and machine learning solutions in other areas of healthcare use similar subscription-based pricing models.